Can Gilead And Merck Capitalize On AstraZeneca/Daiichi Sankyo’s TROP2 Safety Concerns?

Dato-DXd’s Lung Adverse Events Could Scupper NSCLC Goals

 
• By Andrew McConaghie
Gilead_USA
Gilead's Trodelvy is the first TROP2 ADC on the market - Dato-DXd could still outperform it in breast cancer, but safety issues may hamper its progress in NSCLC

More from Clinical Trials

More from R&D